Theranostics Nuclear Medicine in Prostate Cancer.

Bibliographic Details
Title: Theranostics Nuclear Medicine in Prostate Cancer.
Authors: Lima, Helena1 (AUTHOR) he.heleninha@gmail.com, Etchebehere, Marina2 (AUTHOR) etchebeheremarina@gmail.com, Bogoni, Mateos3,4 (AUTHOR) bogonimateos@gmail.com, Torricelli, Caroline5 (AUTHOR) caroltorricelli@gmail.com, Nogueira-Lima, Ellen5 (AUTHOR) ellen.nogueira.lima@gmail.com, Deflon, Victor M.6 (AUTHOR) deflon@iqsc.usp.br, Lima, Mariana5,7 (AUTHOR) marlima1@unicamp.br, Etchebehere, Elba5,7 (AUTHOR) elba@unicamp.br
Source: Pharmaceuticals (14248247). Nov2024, Vol. 17 Issue 11, p1483. 24p.
Subject Terms: *RADIONUCLIDE imaging, *NUCLEAR medicine, *OVERALL survival, *THYROID diseases, *PROSTATE cancer, *IODINE isotopes
Abstract: Theranostic Nuclear Medicine is based on the idea of combining the same molecule (or drug) with different radioisotopes for both diagnosis and treatment, a concept that emerged in the early 1940s with the use of radioactive iodine for thyroid diseases. Theranostic Nuclear Medicine has since expanded to diseases of higher incidence, such as prostate cancer, with several imaging methods used to assess the extent of the disease and the corresponding radiopharmaceuticals used for treatment. For example, by detecting osteoblastic metastases by bone scintigraphy, corresponding radiopharmaceuticals with therapeutic properties can be administered to eliminate or reduce pain associated with metastases and/or determine overall survival gain. The purpose of this review is to discuss the role of Theranostic Nuclear Medicine in prostate cancer, addressing the main diagnostic imaging studies with their corresponding treatments in the Theranostic model. [ABSTRACT FROM AUTHOR]
Copyright of Pharmaceuticals (14248247) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Academic Search Complete
Full text is not displayed to guests.
More Details
ISSN:14248247
DOI:10.3390/ph17111483
Published in:Pharmaceuticals (14248247)
Language:English